CSTONE PHARMA-B (02616): ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Academic Debut

Stock News11-07

CSTONE PHARMA-B (02616) announced that the company will present its autoimmune and inflammation pipeline candidate CS2015 (OX40L/TSLP bispecific antibody) at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in the form of an e-poster and live oral presentation. ACAAI is one of the most influential academic conferences in the fields of allergy, asthma, and immunology, attracting experts and scholars worldwide to discuss the latest scientific advancements. This marks CS2015's first appearance at an international academic conference, with the full abstract and e-poster now officially available on the ACAAI website.

CS2015 features an asymmetric molecular structure, simultaneously targeting OX40L and TSLP—two key regulators of type 2 inflammation clinically validated for effective blockade. The molecule incorporates a mutated Fc to reduce binding with FcγR and extend its in vivo circulation half-life, ultimately optimizing pharmacokinetic (PK) properties to support long dosing intervals. CS2015's outstanding molecular stability ensures the feasibility of developing high-concentration subcutaneous formulations. Additionally, its excellent developability lays the foundation for high-yield and scalable production.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160394698?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160394698","market":"fut","top_or_hot":-1,"title":"CSTONE PHARMA-B (02616): ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Academic Debut","media":"Stock News","content":"<p>CSTONE PHARMA-B (02616) announced that the company will present its autoimmune and inflammation pipeline candidate CS2015 (OX40L/TSLP bispecific antibody) at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in the form of an e-poster and live oral presentation. ACAAI is one of the most influential academic conferences in the fields of allergy, asthma, and immunology, attracting experts and scholars worldwide to discuss the latest scientific advancements. This marks CS2015's first appearance at an international academic conference, with the full abstract and e-poster now officially available on the ACAAI website.</p>\n<p>CS2015 features an asymmetric molecular structure, simultaneously targeting OX40L and TSLP—two key regulators of type 2 inflammation clinically validated for effective blockade. The molecule incorporates a mutated Fc to reduce binding with FcγR and extend its in vivo circulation half-life, ultimately optimizing pharmacokinetic (PK) properties to support long dosing intervals. CS2015's outstanding molecular stability ensures the feasibility of developing high-concentration subcutaneous formulations. Additionally, its excellent developability lays the foundation for high-yield and scalable production.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSTONE PHARMA-B (02616): ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Academic Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSTONE PHARMA-B (02616): ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Academic Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-07 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSTONE PHARMA-B (02616) announced that the company will present its autoimmune and inflammation pipeline candidate CS2015 (OX40L/TSLP bispecific antibody) at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in the form of an e-poster and live oral presentation. ACAAI is one of the most influential academic conferences in the fields of allergy, asthma, and immunology, attracting experts and scholars worldwide to discuss the latest scientific advancements. This marks CS2015's first appearance at an international academic conference, with the full abstract and e-poster now officially available on the ACAAI website.</p>\n<p>CS2015 features an asymmetric molecular structure, simultaneously targeting OX40L and TSLP—two key regulators of type 2 inflammation clinically validated for effective blockade. The molecule incorporates a mutated Fc to reduce binding with FcγR and extend its in vivo circulation half-life, ultimately optimizing pharmacokinetic (PK) properties to support long dosing intervals. CS2015's outstanding molecular stability ensures the feasibility of developing high-concentration subcutaneous formulations. Additionally, its excellent developability lays the foundation for high-yield and scalable production.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1160394698","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160394698","pubTimestamp":1762474478,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSTONE PHARMA-B (02616) announced that the company will present its autoimmune and inflammation pipeline candidate CS2015 (OX40L/TSLP bispecific antibody) at the 2025 American College of Allergy,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","02616":"基石药业-B","TSLP":"TSLA收益溢价策略ETF-Kurv"},"translate_title":"基石药业-B(02616)：ACAAI 2025|CS2015（OX40L/TSLP双特异性抗体）国际学术首发","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSLP":1,"02616":1},"content_text":"CSTONE PHARMA-B (02616) announced that the company will present its autoimmune and inflammation pipeline candidate CS2015 (OX40L/TSLP bispecific antibody) at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in the form of an e-poster and live oral presentation. ACAAI is one of the most influential academic conferences in the fields of allergy, asthma, and immunology, attracting experts and scholars worldwide to discuss the latest scientific advancements. This marks CS2015's first appearance at an international academic conference, with the full abstract and e-poster now officially available on the ACAAI website.\nCS2015 features an asymmetric molecular structure, simultaneously targeting OX40L and TSLP—two key regulators of type 2 inflammation clinically validated for effective blockade. The molecule incorporates a mutated Fc to reduce binding with FcγR and extend its in vivo circulation half-life, ultimately optimizing pharmacokinetic (PK) properties to support long dosing intervals. CS2015's outstanding molecular stability ensures the feasibility of developing high-concentration subcutaneous formulations. Additionally, its excellent developability lays the foundation for high-yield and scalable production.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160394698","isCrawlerRequest":true}